Can Eli Lilly's Two-Drug Obesity Treatment Justify Its $1 Trillion Valuation?

Eli Lilly's roughly $1 trillion valuation faces a key catalyst on September 30, when mid-stage data for its two-drug obesity candidate eloraTZP are due. The readout will determine whether the combination therapy represents a meaningful new obesity franchise opportunity or only incremental benefits that may not justify its development investment and valuation expectations.